BioTime (BTX) Says Two Key Patents Providing Protection to OpRegen Remain Upheld

September 14, 2017 5:44 PM UTC Send to a Friend
BioTime, Inc. (NYSE: BTX), a clinical stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, and its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login